NicOx S.A.
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in P… Read more
Market Cap & Net Worth: NicOx S.A. (ALCOX)
NicOx S.A. (PA:ALCOX) has a market capitalization of $35.68 Million (€34.76 Million) as of March 19, 2026. Listed on the PA stock exchange, this France-based company holds position #23849 globally and #209 in its home market, demonstrating a -4.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NicOx S.A.'s stock price €0.43 by its total outstanding shares 80925718 (80.93 Million).
NicOx S.A. Market Cap History: 2015 to 2026
NicOx S.A.'s market capitalization history from 2015 to 2026. Data shows change from $757.91 Million to $35.68 Million (-25.13% CAGR).
NicOx S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NicOx S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.97x
NicOx S.A.'s market cap is 2.97 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $361.35 Million | $12.91 Million | -$18.10 Million | 28.00x | N/A |
| 2021 | $212.24 Million | $7.23 Million | -$43.76 Million | 29.34x | N/A |
| 2022 | $93.04 Million | $3.27 Million | -$31.29 Million | 28.44x | N/A |
| 2023 | $36.72 Million | $6.90 Million | -$20.88 Million | 5.32x | N/A |
| 2024 | $23.34 Million | $7.86 Million | -$22.39 Million | 2.97x | N/A |
Competitor Companies of ALCOX by Market Capitalization
Companies near NicOx S.A. in the global market cap rankings as of March 19, 2026.
Key companies related to NicOx S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NicOx S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, NicOx S.A.'s market cap moved from $757.91 Million to $ 35.68 Million, with a yearly change of -25.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €35.68 Million | +44.13% |
| 2025 | €24.75 Million | +6.05% |
| 2024 | €23.34 Million | -36.43% |
| 2023 | €36.72 Million | -60.54% |
| 2022 | €93.04 Million | -56.16% |
| 2021 | €212.24 Million | -41.26% |
| 2020 | €361.35 Million | -0.11% |
| 2019 | €361.76 Million | -13.07% |
| 2018 | €416.17 Million | -50.59% |
| 2017 | €842.31 Million | +18.86% |
| 2016 | €708.65 Million | -6.50% |
| 2015 | €757.91 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of NicOx S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.68 Million USD |
| MoneyControl | $35.68 Million USD |
| MarketWatch | $35.68 Million USD |
| marketcap.company | $35.68 Million USD |
| Reuters | $35.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.